Promises and Limitations of Neural Stem Cell Therapies for Progressive Multiple Sclerosis
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Multiple disease-modifying medications with regulatory approval to treat multiple sclerosis (MS) are unable to prevent inflammatory tissue damage in the central nervous system (CNS), and none directly promote repair. Thus, there is an unmet clinical need for therapies that can arrest and reverse the persistent accumulation of disabilities associated with progressive forms of MS (P-MS). Preclinical research has revealed an unexpected ability of neural stem cell (NSC) therapies to provide neurotrophic support and inhibit detrimental host immune responses in vivo following transplantation into the chronically inflamed CNS. We discuss NSC transplantation as a promising therapy for P-MS, elaborate on the necessities of clinical trial validation and formalized usage guidelines, and caution about unscrupulous 'clinics' marketing unproven therapies to patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30470-2 · Cited by 8,167 · cited 2×
“%) present with constant accumulation of disabilities from the onset of symptoms, without early relapses or remissions (so-called primary progressive MS, PP-MS) [8].”
BackgroundThe role of senescent cells in ageing
van Deursen, J. M. (2014) · Nature · doi:10.1038/nature13193 · Cited by 2,623 · cited 1×
“This aging-related loss of function specifically affects neural stem cells (NSCs) and arises from increased oxidative damage, genetic and epigenetic stress, as well as telomere attrition [28].”
BackgroundReich, D. S., Lucchinetti, C. F., & Calabresi, P. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1401483 · Cited by 2,491
Hammond, T. R., Dufort, C., Dissing-Olesen, L., Giera, S., Young, A., Wysoker, A., Walker, A. J., Segel, M., Nemesh, J., Saunders, A., et al. (2018) · doi:10.1101/406140 · Cited by 2,225
Immunopathology of multiple sclerosis
Dendrou, C. A., Fugger, L., & Friese, M. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3871 · Cited by 2,215
Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution
Masuda, T., Sankowski, R., Staszewski, O., Böttcher, C., Amann, L., Sagar, Scheiwe, C., Nessler, S., Kunz, P., van Loo, G., et al. (2019) · Nature · doi:10.1038/s41586-019-0924-x · Cited by 1,310 · cited 8×
“Specific populations of chronically activated MPs include both tissue-resident (i.e., microglia and non-parenchymal macrophages) and infiltrating MPs (i.e., macrophages entering the CNS via the bloodstream).”
BackgroundInfluentialAltered human oligodendrocyte heterogeneity in multiple sclerosis
Jäkel, S., Agirre, E., Mendanha Falcão, A., van Bruggen, D., Lee, K. W., Knuesel, I., Malhotra, D., ffrench-Constant, C., Williams, A., & Castelo-Branco, G. (2019) · Nature · doi:10.1038/s41586-019-0903-2 · Cited by 854
Human Adult Neurogenesis: Evidence and Remaining Questions
Kempermann, G., Gage, F. H., Aigner, L., Song, H., Curtis, M. A., Thuret, S., Kuhn, H. G., Jessberger, S., Frankland, P. W., Cameron, H. A., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.04.004 · Cited by 790 · cited 1×
“The intrinsic regenerative potential of the adult human brain strikingly decreases with time after birth, as well as in the context of disease and physiological aging [27].”
BackgroundLoss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis
Zrzavy, T., Hametner, S., Wimmer, I., Butovsky, O., Weiner, H. L., & Lassmann, H. (2017) · Brain · doi:10.1093/brain/awx113 · Cited by 684
Regenerating CNS myelin — from mechanisms to experimental medicines
Franklin, R. J. M., & ffrench-Constant, C. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.136 · Cited by 647 · cited 2×
“Studies in rodent models of MS have suggested the potential for the generation of new oligodendrocytes from oligodendrocyte precursor cells (OPCs) as a viable mechanism to enhance remyelination [12].”
Background
Cited by
The role of neural stem cells in regulating glial scar formation and repair
Nicaise, A. M., D’Angelo, A., Ionescu, R.-B., Krzak, G., Willis, C. M., & Pluchino, S. (2022) · Cell and Tissue Research · doi:10.1007/s00441-021-03554-0 · Cited by 65
Self-citationIonescu, R.-B., Nicaise, A. M., Reisz, J. A., Williams, E. C., Prasad, P., Willis, C. M., Simões-Abade, M. B. C., Sbarro, L., Dzieciatkowska, M., Stephenson, D., et al. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.09.014 · Cited by 34
Self-citationNeural Stem Cell‐Derived Extracellular Vesicles for Advanced Neural Repair
Moretti, E. H., Lin, A. L. Y., Peruzzotti‐Jametti, L., Pluchino, S., & Mozafari, S. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70170 · Cited by 16
“Their ability to secrete bioactive molecules positions them as promising candidates for promoting neural repair and regeneration (Pluchino et al. 2020; Ottoboni et al. 2020; Willis, Nicaise, Hamel, et al. 2020; Willis et al. 2022; Willis, Nicaise, Peruzzotti-Jametti, and Pluchino 2020).”
InfluentialSelf-citationMozafari, S., Deboux, C., Laterza, C., Ehrlich, M., Kuhlmann, T., Martino, G., & Baron‐Van Evercooren, A. (2021) · Glia · doi:10.1002/glia.23950 · Cited by 13
“Yet, an increasing body of evidences support that NPC's neuroprotective effect on endogenous cells occurs via cytokines and/or neurotrophic factors (Laterza et al., 2013; Marteyn et al., 2016; Ottoboni et al., 2020; Pluchino et al., 2020).”
BackgroundHermann, D. M., Bacigaluppi, M., Bassetti, C. L., Bassotti, G., Boltze, J., Chan, A., Dalkara, T., Denes, A., Diez-Tejedor, E., Dodel, R., et al. (2025) · Exploration of Neuroscience · doi:10.37349/en.2025.1006106 · Cited by 13
Self-citation
Metadata
- Authors
- Pluchino, S., Smith, J. A., & Peruzzotti-Jametti, L.
- Venue
- Trends in Molecular Medicine
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 26
- Issue
- 10
- Pages
- 898-912
- ISSN
- 1471-4914 (ISSN-L)
- OpenAlex
- W3028387788
- Cited by
- 59
- References
- 19
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Promises and Limitations of Neural Stem Cell Therapies for Progressive Multiple Sclerosis. https://app.cochat.ai/papers/10.1016/j.molmed.2020.04.005
- The paper
- Pluchino, S., Smith, J. A., & Peruzzotti-Jametti, L. (2020). Promises and Limitations of Neural Stem Cell Therapies for Progressive Multiple Sclerosis. Trends in Molecular Medicine. https://doi.org/10.1016/j.molmed.2020.04.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.